Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2708 | Only Standard Treatment Wiki | 0.58 |
| drug1961 | Interferon alfa Wiki | 0.58 |
| drug2117 | Lenzilumab Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 3 clinical trials
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo.
The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population. ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts. ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus. ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection. ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection. Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection. It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.
Description: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)
Measure: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab) Time: 3 months from baseline.Description: incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)
Measure: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing Time: 3 months from baseline.Description: incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .
Measure: incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab . Time: 28 days from baselineDescription: incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). Assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)
Measure: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing Time: 28 days from baselineDescription: composite outcome: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records
Measure: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records Time: 60 days from baselineDescription: time to clinical improvement (defined as a two point reduction in clinical progress ordinal scale) or discharge from hospital, whichever occurs first. assessed using medical records
Measure: time to clinical improvement or discharge from hospital assessed using medical records Time: 28 days from baselineDescription: ARM 1, secondary endpoint 1 Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. (composite either COVID-19 or other respiratory viral infection). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool Time: 120 days from baselineDescription: ARM 1, secondary endpoint 2 Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records
Measure: ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 3. Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records
Measure: ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 4 Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale Time: 120 days from baselineDescription: ARM 1, secondary endpoint 5 Incidence of unplanned all-cause hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records
Measure: ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 6 Incidence of unplanned infection-related hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records
Measure: ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 7 Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR
Measure: ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR Time: 120 days from baselineDescription: ARM 1, secondary endpoint 8 Incidence of death from any cause during the study period. assessed using patient medical records
Measure: ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records Time: 120 days from baselineDescription: ARM 1, secondary endpoint 9 Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records
Measure: ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records Time: 120 days from baselineDescription: ARM 2: secondary outcome 1. Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period (days). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records. Time: 28 days from baselineDescription: ARM 2: secondary outcome 2. Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records
Measure: ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records Time: 28 days from baselineDescription: ARM 2: secondary outcome 3. Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale. Time: 28 days from baselineDescription: ARM 2: secondary outcome 4. Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.
Measure: ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records. Time: 28 days from baselineDescription: ARM 2: secondary outcome 5 Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records
Measure: ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records Time: 28 days from baselineDescription: ARM 2: secondary outcome 6 Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.
Measure: ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR. Time: 28 days from baselineDescription: ARM 2: secondary outcome 7. Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records
Measure: ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records Time: 28 days from baselineDescription: ARM 3: secondary outcome 1 Time to clinical improvement defined as Resolution of fever - oral temperature < 38oC for 24 hours without antipyretics AND Respiratory rate < 20 breaths/minute OR Oxygen saturation > 94% on room air OR Hospital discharge assessed using medical records
Measure: ARM 3: Time to clinical improvement assessed using medical records. Time: 60 days from baselineDescription: ARM 3: secondary outcome 2. Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)
Measure: ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale Time: 60 days from baselineDescription: ARM 3: secondary outcome 3 change to clinical condition assessed with Karnofsky Performance score
Measure: ARM 3: change to clinical condition assessed with Karnofsky Performance score Time: 60 days from baselineDescription: ARM 3: secondary outcome 4. Time to progression to severe COVID-19, defined by WHO ordinal scale
Measure: ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale Time: 60 days from baselineDescription: ARM 3: secondary outcome 5 Time to all-cause mortality
Measure: ARM 3: Time to all-cause mortality Time: 60 days from baselineDescription: ARM 3: secondary outcome 6. Duration of hospitalisation. assessed using medical records
Measure: ARM 3:Duration of hospitalisation assessed using medical records Time: at discharge or day 60 whichever is soonerDescription: ARM 3: secondary outcome 7 Duration of COVID-19 symptoms assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.
Measure: ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary. Time: 60 days from baselineDescription: ARM 3: secondary outcome 8. Duration of oxygen supplementation (days). assessed using medical records.
Measure: ARM 3: Duration of oxygen supplementation (days). assessed using medical records. Time: 60 days from baselineDescription: ARM 3: secondary outcome 9 change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)
Measure: ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR) Time: 60 days from baselineDescription: ARM 3: secondary outcome 10. Safety and tolerability of selinexor defined as listing and documentation of frequency and severity of adverse effects. Outcome assessed using any/all of medical records, patient reported, vital signs, ECG, imaging, other investigative procedure as per standard local practice.
Measure: ARM 3: Safety and tolerability of selinexor using relevant medical records Time: 60 days from baselineDescription: ARM 3: secondary outcome 11. composite outcome: incidence of changes in blood results relevant to clinical improvement. Changes in C-reactive protein (CRP) Changes in ferritin level Changes in lactate dehydrogenase (LDH) level
Measure: ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records Time: 60 days from baselineDescription: ARM 4: secondary outcome 1 Incidence of all cause death by day 28 and 60 assessed using medical records
Measure: ARM 4: Incidence of all cause death by day 28 and 60 Time: day 28 from baseline and day 60 from baselineDescription: ARM 4: secondary outcome 2 Time to all-cause mortality assessed using medical records
Measure: ARM 4: Time to all-cause mortality Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 3 - composite outcome: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death) Proportion who have recovered (defined as 0-4) Proportion who had 1 point improvement Proportion who had 2 point improvement
Measure: ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 4 Incidence of ARDS. assessed using medical records
Measure: ARM 4: Incidence of ARDS assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 5 incidence of HLH. assessed using medical records
Measure: ARM 4: incidence of HLH. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 6 Duration of hospitalisation. assessed using hospital medical records.
Measure: ARM 4: Duration of hospitalisation. assessed using hospital medical records. Time: at discharge or by day 60 whichever is soonerDescription: ARM 4: secondary outcome 7 Proportion discharged from hospital. assessed using medical records
Measure: ARM 4: Proportion discharged from hospital. assessed using medical records Time: at dischargeDescription: ARM 4: secondary outcome 8. Incidence of mechanical ventilation up to day 28. assessed using medical records
Measure: ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records Time: any time up day 28 from baselineDescription: ARM 4: secondary outcome 9 composite outcome: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records
Measure: ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 10. composite outcome: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.
Measure: ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 11 composite outcome: Incidence and duration of ICU admission. assessed using medical records
Measure: ARM 4: Incidence and duration of ICU admission. assessed using medical records Time: at discharge or by day 60 from baseline.Description: ARM 4: secondary outcome 12 composite outcome: incidence and duration of supplemental oxygen use. assessed using medical records
Measure: ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 13. Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours. assessed using medical records
Measure: ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 14 incidence of non-invasive ventilation. assessed using medical records
Measure: ARM 4: incidence of non-invasive ventilation. assessed using medical records Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 15. composite outcome: number of participants alive and off oxygen at day 60. assessed using medical records.
Measure: ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records. Time: any time up to 60 days from baselineDescription: ARM 4: secondary outcome 16 proportion of participants who had improved oxygenation for >48 hours. assessed using medical records
Measure: ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records Time: any time up to 28 days from baselineDescription: ARM 4: secondary outcome 17 Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records
Measure: ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records Time: any time up to day 28 from baseline.Description: ARM 4: secondary outcome 18 incidence of SAEs based on NCI CTCAE v5 assessed using medical records
Measure: ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records Time: any time up to 28 days from baseline.Description: ARM 4: secondary outcome 19 change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.
Measure: ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR. Time: any time up to day 60 from baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports